Mimedx Group Inc

Research Mimedx Group Inc (MDXG) on Bullrun: valuation model: 25.3% undervalued, market cap USD 582.38M, P/E 19.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMDXG
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal25.3% undervalued
• Market capUSD 582.38M
• P/E19.1
• Financial periodFY2025
• RevenueUSD 418.63M
• Revenue growth20.0%
• Net incomeUSD 48.58M
• Gross margin82.6%

Valuation Snapshot

Bullrun's latest valuation model marks Mimedx Group Inc as 25.3% undervalued; latest market cap is USD 582.38M; P/E is 19.1.

About Mimedx Group Inc

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.

Frequently asked questions

Is Mimedx Group Inc overvalued or undervalued?

Bullrun's valuation model currently marks Mimedx Group Inc as 25.3% undervalued.

What is Mimedx Group Inc's market cap?

Mimedx Group Inc's market capitalization is USD 582.38M.

What is Mimedx Group Inc's P/E ratio?

Mimedx Group Inc's price-to-earnings (P/E) ratio is 19.1.

What does Mimedx Group Inc do?

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains...